To the Editor: Packer et al. (Jan. 30 issue) 1 report the highly anticipated results of the SUMMIT trial, which compared tirzepatide with placebo in patients with heart failure with preserved ...

Jaime Almandoz, MD, MBA, of UT Southwestern Medical Center, speaks on results of a study that investigated tirzepatide uptake trends in commercial claims data. A recent article published in Annals ...

Please provide your email address to receive an email when new articles are posted on . Tirzepatide use increased significantly since January 2021, particularly among people without diabetes.

Tirzepatide, the active ingredient in Lilly's Zepbound and Mounjaro for Type 2 diabetes, was in shortage for two years until Dec. 19, 2024. The U.S. Food and Drug Administration required an end to ...

HealthDay News — After approval, tirzepatide dispensations increased markedly among adults with type 2 diabetes prescribed glucose-lowering medications (GLMs) and among adults without diabetes ...

New data documented dramatic shifts in prescribing for both type 2 diabetes (T2D) and weight loss, particularly with the uptake of tirzepatide (Lilly) and declines in the use of older agents.